DSIP vs Metformin
Emerging vs FDA Approved
monitor Mechanism-based · 46% Both DSIP and Metformin enhance GABAergic activity. Combined CNS depression increases risk of excessive sedation, respiratory depression, and impaired coordination. Do not combine with alcohol.
Molecular Data
DSIP Metformin
Weight 848.81 Da 129.16 Da
Half-life ~15 minutes (in vitro) ~5 hours
Chain 9 amino acids —
Type Nonapeptide Biguanide (C4H11N5)
Key Benefits
DSIP
01 Enhanced sleep quality through slow-wave sleep promotion
02 Stress reduction via cortisol modulation
03 Potential pain relief
04 Mood stabilization without traditional sedative effects
05 No tolerance or dependence reported
06 Short cycle duration (5-10 days)
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Dosing Protocols
DSIP
100-300mcg / 1x daily
Sleep enhancement 100-200mcg Once nightly
Chronic pain support 250-300mcg Daily
Stress management 150mcg Evening
Withdrawal support 200-300mcg Twice daily
Athletic recovery 100-150mcg Post-training
Metformin
500-2000 mg/day / 1-2x daily with meals
Side Effects
DSIP
Generally well-tolerated with minimal side effects
Mild drowsiness or dizziness initially (some users)
Occasional headaches in sensitive individuals
No tolerance or dependence reported in studies
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
Avoid driving until effects are known
Pregnancy or breastfeeding
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
DSIP Metformin
Status Emerging FDA Approved
References 6 studies 5 studies
Latest 2006 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.